Evaluation of a novel high-capacity dry plasma biosampling-lateral flow device for the testing of traumatic brain injury protein biomarkers
Kobeissy et al.
The finding, in our words
The DPB-LF device collected capillary blood and generated dried plasma that showed strong correlation with wet plasma for four traumatic brain injury biomarkers, with R² values between 0.83 and 0.99. Samples remained stable at 4 °C and predicted cranial lesions on computed tomography with areas under the curve of 0.70–0.76, providing a patient‑centric microsampling approach that removes cold‑chain requirements for decentralised TBI diagnostics.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
The homeRNA capillary blood collection and stabilization platform successfully captured lipopolysaccharide-induced inflammatory gene expression profiles. These transcriptomic responses were comparable to those obtained from traditional venous blood samples stabilized with RNAlater or PAXgene, demonstrating the platform's suitability for remote transcriptomic monitoring.
Capillary finger-stick dried blood spots demonstrated strong analytical agreement with venous serum for prostate-specific antigen (R² = 0.987) and remained stable for 31 days across a wide temperature range. This less invasive microsampling approach enables at-home self-collection, supporting decentralised screening and tele-diagnostics for prostate cancer.
ALAS2 and CA1 mRNA were reliably quantified from venous-cellulose, capillary-cellulose and Tasso-M20 dried blood spots with strong linear agreement (r ≥ 0.96) and no bias for ALAS2. CA1 showed modest proportional bias of 9-22% only when Tasso-M20 was compared with cellulose cards in the rEPO cohort, but no significant differences in relative expression across matrices were observed at any timepoint. These findings support decentralised capillary sampling for longitudinal anti-doping monitoring.
A validated offline SPE-LC-MS/MS method using the Mitra microsampling device successfully quantified tacrolimus, cyclosporine A, tryptophan, kynurenine, and creatinine simultaneously. The method met EMA and FDA criteria, showing agreement between capillary and venous sampling, which could facilitate decentralised therapeutic drug monitoring and transplant follow-up through patient self-collection.